Skip to main content
Fig. 6 | BMC Neurology

Fig. 6

From: Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE

Fig. 6

a Change from baseline to 1 and 2 years in SDMT score, b percentage of patients with clinically significant improvement in SDMT score (defined as an increase ≥4 points) at 1 and 2 years, c change in SDMT score from baseline to 2 years by baseline characteristics, and d change from baseline to 1 and 2 years in MSIS-29 physical, psychological, and quality-of-life scores. p-values are based on a paired t-test. CI = confidence interval; MSIS-29 = Multiple Sclerosis Impact Scale; SDMT = Symbol Digits Modality Test

Back to article page